Citadel Advisors
CGEM icon

Citadel Advisors’s Cullinan Oncology CGEM Stock Holding History

Citadel Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.24M Buy
397,484
+144,706
+57% +$2.15M ﹤0.01% 4098
2026
Q1 		$3.59M Buy
252,778
+142,461
+129% +$1.83M ﹤0.01% 4917
2025
Q4 		$1.14M Sell
110,317
-1,874,090
-94% -$16.9M ﹤0.01% 7100
2025
Q3 		$11.8M Sell
1,984,407
-629,286
-24% -$4.61M ﹤0.01% 3024
2025
Q2 		$19.7M Sell
2,613,693
-133,452
-5% -$1.07M ﹤0.01% 2154
2025
Q1 		$20.8M Buy
2,747,145
+64,241
+2% +$616K ﹤0.01% 1994
2024
Q4 		$32.7M Buy
2,682,904
+727,647
+37% +$10.5M 0.01% 1663
2024
Q3 		$32.7M Buy
1,955,257
+12,118
+0.6% +$215K 0.01% 1595
2024
Q2 		$33.9M Buy
1,943,139
+833,968
+75% +$17.8M 0.01% 1494
2024
Q1 		$18.9M Sell
1,109,171
-23,718
-2% -$366K ﹤0.01% 2126
2023
Q4 		$11.5M Buy
1,132,889
+67,841
+6% +$601K ﹤0.01% 2649
2023
Q3 		$9.64M Buy
1,065,048
+8,697
+0.8% +$90.6K ﹤0.01% 2726
2023
Q2 		$11.4M Buy
1,056,351
+433,283
+70% +$4.6M ﹤0.01% 2510
2023
Q1 		$6.37M Buy
623,068
+377,958
+154% +$4.17M ﹤0.01% 3423
2022
Q4 		$2.59M Buy
245,110
+9,507
+4% +$115K ﹤0.01% 5010
2022
Q3 		$3.02M Sell
235,603
-133,867
-36% -$1.8M ﹤0.01% 4797
2022
Q2 		$4.74M Buy
369,470
+229,785
+165% +$2.61M ﹤0.01% 3896
2022
Q1 		$1.46M Buy
139,685
+93,204
+201% +$1.26M ﹤0.01% 6791
2021
Q4 		$717K Sell
46,481
-59,652
-56% -$1.19M ﹤0.01% 8772
2021
Q3 		$2.4M Buy
106,133
+3,025
+3% +$80.9K ﹤0.01% 5905
2021
Q2 		$2.65M Sell
103,108
-8,214
-7% -$253K ﹤0.01% 5899
2021
Q1 		$4.64M Buy
+111,322
New +$4.52M ﹤0.01% 4411

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Citadel Advisors's CGEM Position: Q2 2026 in Review

Citadel Advisors increased its Cullinan Oncology (CGEM) stake by 57% in Q2 2026, buying an estimated $2.15M and bringing the position to 397,484 shares worth $7.24M. The position accounts for ﹤0.01% of the portfolio, ranked #4098.

Citadel Advisors first reported a position in CGEM in Q1 2021 and has held it in 22 quarters since. The position peaked at $33.9M in Q2 2024. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Citadel Advisors held 397,484 shares of Cullinan Oncology worth $7.24M as of Q2 2026.
  • Citadel Advisors bought 144,706 Cullinan Oncology shares in Q2 2026, an estimated $2.15M.
  • Cullinan Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4098 holding.
  • Citadel Advisors first reported a position in Cullinan Oncology in Q1 2021 and has held it in 22 quarters since.
  • Citadel Advisors's Cullinan Oncology position peaked at $33.9M in Q2 2024.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.